| payload |
{"created_at":"2026-04-22T03:03:32.063 {"created_at":"2026-04-22T03:03:32.063787+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:25590e808969d61f","evidence_event_ids":["evt_f63634d9d75a"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166731.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166731.txt","company":"Solid Biosciences Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166731.txt","article_chars":2549,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_35e5228eb5a6c026","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166731.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:28:21.716397+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166731.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166731.txt","source_event_id":"evt_f63634d9d75a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"5c15f61c8a93093d","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-21","2026-01-29","2027-01-01","2024-06-11"],"entities":[{"asset_class":"equity","name":"Solid Biosciences Inc.","relevance":"high","symbol":"SLDB","type":"issuer"},{"asset_class":"person","name":"Jessie Hanrahan","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Common Stock","relevance":"high","symbol":"","type":"security"}],"event_type":"listing","information_gaps":["The cleaned text does not explicitly state whether the Form 4 reflects a purchase, sale, or vesting event; it only provides narrative descriptions of RSUs/PSUs and the performance milestone timing.","The filing values include numbers (e.g., 54925) but the specific mapping to the transaction type (e.g., acquired vs vested) is not fully explicit in the provided excerpt.","No prior known state is included in the prompt, so the exact 'delta vs prior' change cannot be determined from the provided text alone."],"key_facts":["SEC filing: Form 4 (conformed submission type: 4).","Issuer: Solid Biosciences Inc. (CIK: 0001707502).","Reporting owner: Jessie Hanrahan (CIK: 0001954826).","Filing date (filed as of date): 2026-04-21; period of report (conformed period of report): 2026-01-29.","Security described: Restricted Stock Units (RSUs), where each RSU represents a contingent right to receive one share of the issuer\u2019s common stock.","PSUs were granted on June 11, 2024 and vest 25% of the target number of underlying RSUs upon achievement of each of four independent performance milestones.","The performance criteria for the second performance milestone was determined by the Board to be met on January 29, 2026.","Shares related to the second performance milestone will vest subject to the grantee\u2019s continued service with the Company on the evaluation date, anticipated to occur in the first quarter of 2027.","The filing includes a signature dated 2026-04-21 (/s/ Kimberly Cornwell as attorney-in-fact for Jessie Hanrahan)."],"numeric_claims":[{"label":"RSUs/underlying shares reported (value shown)","value":"54925"},{"label":"RSU price (value shown)","value":"0.00"},{"label":"Number of RSUs/underlying shares (transaction/shares shown)","value":"54925"}],"primary_claim":"On 2026-04-21, Solid Biosciences Inc. filed Form 4 showing Jessie Hanrahan\u2019s RSU/PSU award details, including a performance milestone determined met on 2026-01-29 with vesting anticipated in Q1 2027.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Solid Biosciences Inc. filed a Form 4 on 2026-04-21 reporting Jessie Hanrahan\u2019s equity award activity related to restricted stock units (RSUs) and performance stock units (PSUs). The filing indicates PSUs tied to a performance milestone determined as met on 2026-01-29, with vesting expected in Q1 2027 subject to continued service.","topics":["SEC Form 4","insider ownership","RSUs","PSUs","performance milestone","vesting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Solid Biosciences Inc. \u00b7 Filed 20260421","ticker":"SLDB","tickers":["SLDB"],"title":"SLDB filed 4","url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166731.txt"}}... |